Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease.

Trial Profile

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease.

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Tamibarotene (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 14 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top